Citations

Showing 10 of 108162 citations.

Transparency and Public Reporting: Beyond the Gathering Storm
Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | November 25, 2019 | Volume: 11 | Issue: 1 | Pages: 9-13

10.1177/2150135119890514 | PMID 31763934 Get It

Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease
Palmer, Melissa , Regev, Arie , Lindor, Keith D. , Avigan, Mark, Dimick‐Santos, Lara, Treem, William R. , Marcinak, John , Lewis, James H. , Anania, Frank A. , Seekins, Daniel, Shneider, Benjamin L. , Chalasani, Naga , Lindor, Keith

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 25, 2019 | Volume: 51 | Issue: 1 | Pages: 90-109

10.1111/apt.15579 | PMID 31762074 Get It

SummaryBackgroundImproved knowledge of the molecular pathophysiology and immunopathogenesis of cholestatic liver diseases in recent years has led to an increased interest in developing novel therapies. Patients with cholestatic liver disease often require different approaches to assessment and management of suspected drug‐induced liver injury (DILI) compared to those with healthy livers and those with parenchymal liver diseases. At present, there are no regulatory guidelines or society position papers, that systematically address best practices pertaining to detection of DILI in these patients.AimsTo outline best practices for detection, assessment and management of suspected acute DILI during clinical trials in adults with the cholestatic liver diseases – Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC).MethodsThis is one of the several papers developed by the IQ DILI Initiative, which is comprised of members from 16 pharmaceutical companies, in collaboration with DILI experts from academia and regulatory agencies. The contents are the result of an extensive literature review, as well as in‐depth discussions among industry, regulatory and academic DILI experts, to achieve consensus recommendations on DILI‐related issues occurring during clinical trials for cholestatic liver diseases.ResultsRecommended best practices are outlined pertaining to hepatic eligibility criteria, monitoring of liver tests, approach to a suspected DILI signal, and hepatic discontinuation rules.ConclusionsThis paper provides a framework for the approach to detection, assessment and management of suspected acute DILI occurring during clinical trials in adults with cholestatic liver disease.
Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies
Sterner, Rosalie M. , Kenderian, Saad S.

Mayo Clinic

Current Opinion in Hematology | November 25, 2019 | Volume: 27 | Issue: 1 | Pages: 41-48

10.1097/moh.0000000000000559 | PMID 31764168 Get It

Purpose of review Chimeric antigen receptor (CAR)-T-cell therapy is a revolutionary tool in the treatment of cancer. CAR-T cells exhibit their effector functions through the recognition of their specific antigens on tumor cells and recruitment of other immune cells. However, this therapy is limited by the development of severe toxicities and modest antitumor activity in solid tumors. The host and tumor microenvironment interactions with CAR-T cells play an important role in orchestrating CAR-T-cell functions. Specifically, myeloid lineage cells and their cytokines critically influence the behavior of CAR-T cells. Here, we review the specific effects of myeloid cell interactions with CAR-T cells, their impact on CAR-T-cell response and toxicities, and potential efforts to modulate myeloid cell effects to enhance CAR-T-cell therapy efficacy and reduce toxicities. Recent findings Independent studies and correlative science from clinical trials indicate that inhibitory myeloid cells and cytokines contribute to the development of CAR-T-cell-associated toxicities and impairment of their effector functions. Summary These findings illuminate a novel way to reduce CAR-T-cell-associated toxicities and enhance their efficacy through the modulation of myeloid lineage cells and inhibitory cytokines.
Left ventricular diastolic dysfunction in HIV-uninfected infants exposed in utero to antiretroviral therapy
Lipshultz, Steven E. , Sasaki, Nao , Eidem, Benjamin W., Cheng, Irene H. , O'Brien, Sharon , Amdani, Shahnawaz , Miller, Tracie L. , Thompson, Bruce , Cheng, Irene, Colan, Steven D. , O’Brien, Sharon E., Shearer, William T. , Orav, E. John , Wilkinson, James D.

Mayo Clinic

AIDS | November 25, 2019 | Volume: 34 | Issue: 4 | Pages: 529-537

10.1097/qad.0000000000002443 | PMID 31764073 Get It

Objectives: To longitudinally measure LV diastolic function in HIV-exposed but uninfected (HEU) children perinatally exposed to ART. Design: HEU children who were perinatally exposed to antiretroviral therapy (ART) may be at risk for adverse cardiac effects. We have previously reported that those children have decreased left ventricular (LV) mass, dimension, and septal thickness with increased contractility. Methods: Serial echocardiograms were obtained at specific times from birth to 48 months from two groups of HIV-uninfected children: 148 HIV-negative children who were perinatally exposed to ART and 130 non-ART-exposed HIV-unexposed healthy controls. The following LV diastolic indices were obtained: mitral valve early and late diastolic velocity (E and A), tissue Doppler-derived LV-free wall and septal early diastolic velocity (LV e′ and sep e′). Results: All echocardiographic indices were significantly different in ART-exposed children compared with ART-unexposed healthy controls. Both E and A were overall lower at all ages by 8.28 cm/s (P = 0.0002) and 13.46 cm/s (P < 0.0001) respectively. E/A ratio was higher by 0.27, 0.46, and 0.28 units at birth, 1 year and 2 years of age, respectively (all P ≤ 0.01). Moreover, LV e′ and sep e′ were overall lower at all ages by 0.84 cm/s (P = 0.01) and 0.47 cm/s (P = 0.02), respectively. Conclusion: Children who were exposed to ART in utero have subclinical yet significant differences in specific LV diastolic indices. Follow-up with serial echocardiograms are recommended in this population to further assess the potential cardiac toxicity of perinatal exposure to ART.
Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005–2014
Cheungpasitporn, Wisit , Ungprasert, Patompong , Kaewput, Wisit , Cheungpasitporn, Wisit , Kaewput, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn , Mao, Michael A. , Aeddula, Narothama Reddy , Kröner, Paul T.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | November 25, 2019 | Volume: 32 | Issue: 5 | Pages: 650-655

10.1097/meg.0000000000001598 | PMID 32267653 Get It

Background This study aimed to evaluate the hospitalization rate for Hepatitis A virus (HAV) among kidney transplant (KTx) recipients and its outcomes as well as resource utilization. Methods The 2005–2014 National Inpatient Sample database was used to identify all hospitalized KTx recipients with an associated diagnosis of HAV. The hospital mortality, resource utilization, and associated liver conditions were compared between patients with and without HAV, adjusting for potential confounders. Results Of 871 024 KTx recipients identified, 204 had HAV. The overall inpatient prevalence of HAV in KTx recipients over 10 years in the United States was 23.42 cases per 100 000 admissions. There were no statistically significant changes in the inpatient prevalence of HAV in KTx recipients during the study period (P = 0.77), ranging from 9.2 to 34.3 per 100 000 admissions. Among hospitalized KTx recipients with HAV, 27.9% were from Northeast, 29.2% were from Midwest, 23.8% were from South, and 19.1% were from West. HAV was not significantly associated with increased hospital mortality, multiorgan failure, need for abdominal ultrasound, hospital length of stay, and total hospitalization costs and charges when compared with those without HAV. However, it is significantly associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure. Conclusion Overall, inpatient prevalence of HAV in KTx recipients in the United States (years 2005–2014) was 23.42 cases per 100 000 admissions. Hospitalization for HAV after KTx is associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure.
Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer
Sharma, Akanksha , Mountjoy, Luke , Butterfield, Richard , Ross, Helen J. , Daniels, T.B., Paripati, Harshita, Mrugała, Maciej M. , Vora, Sujay A., Patel, Naresh P. , Zimmerman, Richard S. , Ashman, Jonathan B. , Porter, Alyx B. , Patel, Naresh P , Zhang, Nan , Schild, Steven E. , Sio, Terence T.

Mayo Clinic

American Journal of Clinical Oncology | November 25, 2019 | Volume: 43 | Issue: 2 | Pages: 128-132

10.1097/coc.0000000000000642 | PMID 31764021 Get It

Objective:Radiation therapy (RT) is the primary treatment of intracranial metastasis (ICM) from lung cancer (LC). Radiation necrosis (RN) has been reported post-RT with an incidence of 5% to 24%. We reviewed the spectrum of imaging changes in patients treated with RT for ICM from LC in an effort to identify potential risk factors for RN.Methods:We reviewed 63 patients with LC and ICM who received RT (radiosurgery [stereotactic radiosurgery] with/without whole brain radiation therapy) at our institution between 2013 and 2018. Data evaluated included demographics, tumor type, ICM burden and location, chemotherapy, surgery, and RT details as well as treatment choices and outcomes.Results:Of the 63 patients, clinical and radiographic criteria for RN were noted in 24 (38%) as early as 2 months and as late as 5 years posttreatment. Six patients required surgical resection due to refractory symptoms revealing pathology-proven RN and occasionally tumor. Patients were significantly more likely to develop RN if they had surgical resection of an ICM (45.8% vs. 20.5%,P=0.05). No differences were found in location, size, or genetic profile of lesions. In total, 80% of patients received treatment for symptoms and/or radiographic change. This was generally a combination of steroids, bevacizumab, laser interstitial thermal treatment, or surgical resection. Most patients required >1 treatment modality.Conclusions:This review of outcomes of RT for ICM in LC demonstrates a higher rate of RN than previously reported in the literature in those having had a surgical resection plus stereotactic radiosurgery. Our observation of RN as late as 5 years post-RT for ICM necessitates clinician awareness.
Hypoglycemia in CDG patients due to PMM2 mutations: Follow up on hyperinsulinemic patients
Moravej, Hossein , Altassan, Ruqaiah , Jaeken, Jaak , Enns, Gregory M. , Ellaway, Carolyn , Balasubramaniam, Shanti , Lonlay, Pascale de , Coman, David , Mercimek‐Andrews, Saadet , Morava, Eva , Witters, Peter , Morava, Éva

Mayo Clinic

JIMD Reports | November 25, 2019 | Volume: 51 | Issue: 1 | Pages: 76-81

10.1002/jmd2.12085 | PMID 32071842 Get It

Abstract Background Phosphomannomutase 2 deficiency (PMM2‐CDG) is the most common congenital disorder of glycosylation (CDG). Hypoglycemia has been reported in various CDG including PMM2‐CDG. The frequency and etiology of hypoglycemia in PMM2‐CDG are not well studied. Methods We conducted a systematic review of the literature on genetically and/or biochemically confirmed PMM2‐CDG patients who developed hypoglycemia. Prospective follow‐up information on the patients who received diazoxide therapy was collected and evaluated. Results A total of 165 peer‐reviewed articles reporting on 933 PMM2‐CDG patients were assessed. Hypoglycemia was specifically mentioned only in 23 of these patients (2.5%). Hyperinsulinism was identified in 10 patients (43% of all hypoglycemic patients). Among these 10 patients, seven were successfully treated with diazoxide. However, most patients remained on therapy longer than a year to stay free of hypoglycemia. Conclusion Hypoglycemia is a rarely reported finding in patients with PMM2‐CDG. Diazoxide‐responsive hyperinsulinism was found to have a good prognosis on medication in our PMM2‐CDG patients with hypoglycemia. No genotype‐phenotype correlation was observed with respect to hyperinsulinism. A prospective study should be undertaken to explore the hypothesis that hypoglycemia is underdiagnosed in PMM2‐CDG and to evaluate whether hyperinsulinism is always associated with hypoglycemia.
Comparison of Disease-related Knowledge of Patients With Inflammatory Bowel Disease Between the West and the East Using an Updated Questionnaire (IBD-KNOW)
Kim, Jin Yong , Yoon, Hyuk , Hwang, Jun Seong , Yang, Suk‐Kyun , Park, Sang Hyoung , Loftus, Edward V. , Loftus, Edward V

Mayo Clinic

Journal of Clinical Gastroenterology | November 25, 2019 | Volume: 54 | Issue: 8 | Pages: 720-724

10.1097/mcg.0000000000001283 | PMID 31764490 Get It

Goals: The study aimed to compare the level and characteristics of disease-related knowledge of patients with inflammatory bowel disease (IBD) between the West and the East using an international version of a questionnaire regarding knowledge of inflammatory bowel disease (IBD-KNOW). Background: The authors recently developed a new questionnaire regarding IBD-KNOW, which showed excellent test characteristics in Korea. Study: The IBD-KNOW questionnaire was administered to 100 patients with IBD from tertiary referral hospitals in the United States and Korea. Scores were calculated and compared between US and Korean patients, and factors associated with high scores were analyzed. Results: A total of 196 (100 US and 96 Korean) patients with IBD completed the questionnaires. Analysis of the baseline characteristics revealed that male sex, smoking status, disease duration, history of IBD-related operations, family history of IBD, and use of corticosteroids or biologics were significantly different between US and Korean patients. The mean IBD-KNOW score was higher in US patients than in Korean patients (14.8 vs. 11.3; P<0.001). Multivariate analyses showed that a high IBD-KNOW score (top 25%) was associated with a positive family history of IBD (odds ratio, 2.90; P=0.025) in US patients with IBD and with the use of biologics (odds ratio, 3.65; P=0.008) in Korean patients with IBD. Conclusions: The IBD-KNOW questionnaire, an updated assessment tool of IBD-related knowledge, is simple, reliable, and available in various patient populations. IBD-KNOW can be used to identify the factors affecting the level of IBD-related knowledge to improve the quality of care in patients with IBD through a personalized approach.
Rapid‐onset vasodilator responses to exercise in humans: Effect of increased baseline blood flow
Dillon, Gabrielle A. , Shepherd, John R. A. , Casey, Darren P. , Dinenno, Frank A. , Curry, Timothy B. , Ranadive, Sushant M. , Ranadive, Sushant M. , Dinenno, Frank A , Ranadive, Sushant , Joyner, Michael J.

Mayo Clinic

Experimental Physiology | November 25, 2019 | Volume: 105 | Issue: 1 | Pages: 88-95

10.1113/ep088227 | PMID 31762131 Get It

New Findings What is the central question of this study? What is the effect of an elevated baseline blood flow, induced by high‐dose intra‐arterial infusion of either adenosine or ATP, on the rapid‐onset vasodilatory response to a single forearm muscle contraction? What is the main finding and its importance? The peak response to a single contraction is unaffected by augmented baseline blood flow, and thus, is likely to be attributable to a feedforward vasodilatory mechanism. AbstractThe hyperaemic responses to single muscle contractions are proportional to exercise intensity, which, in turn, is proportional to tissue metabolic demand. Hence, we tested the hypothesis that the rapid‐onset vasodilatory response after a single muscle contraction would be unaffected when baseline blood flow was increased via high‐dose intra‐arterial infusion of either adenosine (ADO) or ATP. Twenty‐four healthy young participants (28 ± 1 years) performed a single forearm contraction (20% maximal voluntary contraction) 75 min after commencement of a continuous infusion of ADO (n = 6), ATP (n = 8) or saline (control; n = 10). Brachial artery diameter and blood velocity were measured using Doppler ultrasound. Resting forearm vascular conductance (FVC; in millilitres per minute per 100 mmHg per decilitre of forearm volume) was significantly higher during ADO (33 ± 17) and ATP infusion (33 ± 17) compared with the control infusion (8 ± 3; P < 0.05). The peak FVCs post‐contraction during ADO and ATP infusions were significantly greater than during the control infusion (P < 0.05), but not different from one another. The peak change in FVC from baseline was similar in all three conditions (control, 14 ± 1; ADO, 24 ± 2; and ATP, 23 ± 6; P = 0.15). Total FVC (area under the curve) did not differ significantly between ADO and ATP (333 ± 69 and 440 ± 125); however, total FVC during ATP infusion was significantly greater compared with the control value (150 ± 19; P < 0.05). We conclude that the peak response to a single contraction is unaffected by augmented baseline blood flow and is therefore likely to be attributable to a feedforward vasodilatory mechanism.
How Patient Decision-Making Characteristics Affect Satisfaction in Facial Plastic Surgery: A Prospective Pilot Study
Oliver, Jeremie D. , Menapace, Deanna C., Recker, Chelsey, Friedman, Oren, Oliver, Jeremie D , Staab, Jeffrey P. , Friedman, Oren A , Hamilton, Grant

Mayo Clinic

Plastic & Reconstructive Surgery | November 25, 2019 | Volume: 144 | Issue: 6 | Pages: 1487-1497

10.1097/prs.0000000000006269 | PMID 31764673 Get It

Background: The main objective of this study was to prospectively analyze which personality traits, clinical psychiatric states, and patient decision-making characteristics predict who will be less satisfied after facial plastic surgery. Methods: This prospective study enrolled 60 adult subjects into one of three groups: aesthetic, functional, and reconstructive facial plastic surgery procedures (n = 20 in each group) from November of 2011 to February of 2016. Self-report surveys of personality traits (i.e., NEO Personality Inventory-Revised), psychiatric state (i.e., Patient Health Questionnaire, Generalized Anxiety Disorder, Health Anxiety Inventory–Short Form), and decision-making characteristics (maximizer/satisficer survey) were given during the preoperative clinic visits. In postoperative follow-up, satisfaction questionnaires at 3, 6, and 12 months were administered. Data analysis examined associations between patient satisfaction, decision-making characteristics, and psychiatric variables. Results: Bivariate analyses showed that maximizer/satisficer decision-making style was significantly related to patient satisfaction scores in the year following surgery. This difference reached statistical significance at 6 months and remained a strong trend at 12 months. Patients who were less than extremely satisfied at both postoperative time points were more likely to portray the maximizer decision-making style. No other variables were associated with patient satisfaction at any time point. Maximizer/satisficer survey scores were not associated with self-reports of depression, anxiety, or illness anxiety. Mean scores on the maximizer/satisficer survey did not differ among the aesthetic, functional, and reconstructive groups. Conclusions: The maximizer/satisficer survey captures an aspect of patient care not traditionally measured by standard clinical psychometric screening tools to help predict satisfaction. A short questionnaire targeting consumer decision-making may be a helpful tool for preoperative counseling.